Description of PHOTOGEM® Photosensitizer

PHOTOGEM^®

is the unique photodynamic drug therapy (PDT) of malignant tumours;

does not yield to its analogues in therapeutic activity;

production based on a unique original technology protected by Russia's patents. Our "know-how" allows to simplify the production of the preparation and significantly bring down its cost price;

has ability to selectively accumulate and remain in malignant tumours, and under lighting of the activating wavelength to turn into an upper state. Then it either fluoresces in red (spectrum), or initiates photo-toxic reactions in a growth tissue. The above characteristics allow to use PHOTOGEM® both for the diagnostic of a tumour and for its elimination;

In clinical oncology the PHOTOGEM® PDT courses of radical treatment are indicated in the following cases:

• obligate pre-cancer states (III stage dysplasia);

• pre-invasive and early-stage invasive cancer (Tis, T1N0M0);

• post-radiotherapy residual tumour;

• post-surgical early-stage cancer relapse (and second metachronic cancer).

The PHOTOGEM® PDT courses of palliative treatment are indicated in the following cases:

• constrictive forms of a cancer of bronchus, oesophagus and colon (large intestine);

• non-resectable, resistant to chemo-radiotherapy III-IV stages malignant tumours;

• intracutaneous (endermic) sarcoma, lactic Ferri lactas cancer metastasises.

Localization of tumours: skin, top respiratory tract, trachea, bronchus, oral cavity, esophagus, stomach, rectum and colon, urinary bladder, vagina, cervix of the uterus, endometritis and other tumours accessible for direct or endoscopic laser illumination.

If a residual tumour is detected after the first PDT course, repeated injection of the drug is possible, sessions of PHOTOGEM® PDT treatment should be carried out at a 1 month interval. Because of the low dark toxicity of PHOTOGEM®, PDT treatments are compatible with the surgery, chemo- and radiotherapy.